{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:06:26Z","timestamp":1789560386102,"version":"build-2803163510"},"reference-count":29,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite significant research and investment, antibody\u2013drug conjugates (ADCs) primarily rely on a limited number of broadly cytotoxic payloads that contribute significantly to toxicity. More recently, there has been a migration toward mechanistically targeted payloads, pairing improved antibodies with small molecules that act on disease-specific biology, improving precision and tolerability. Designing these next-generation payloads means rethinking some of our design metrics and guidelines derived from traditional medicinal chemistry: properties such as LogD, pKa, permeability, efflux, and metabolic stability must be carefully balanced to ensure efficient intracellular release while limiting systemic exposure. Here we discuss our observations around these properties and suggest design rules and guidelines for the optimization of next-generation ADC payloads.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00322","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:45:25Z","timestamp":1787431525000},"page":"1798-1803","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Cytotoxic\nPayloads for Antibody Drug Conjugates\u2500A\nMedicinal Chemistry Perspective"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-3993","authenticated-orcid":true,"given":"Allan","family":"Jordan","sequence":"first","affiliation":[{"name":"Sygnature Discovery , Alderley Park , ,","place":["Macclesfield, U.K., SK10 4TG"]},{"name":"Sygnature Discovery, BioCity , Pennyfoot Street , ,","place":["Nottingham, U.K., NG1 1GR"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Best","sequence":"additional","affiliation":[{"name":"Sygnature Discovery , Alderley Park , ,","place":["Macclesfield, U.K., SK10 4TG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Greally","sequence":"additional","affiliation":[{"name":"Sygnature Discovery , Birchwood House, Larkwood Way, Tytherington Business Park , , ,","place":["Macclesfield, Cheshire, U.K., SK10 2XR"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026091607070401400_cit1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/B978-0-08-009056-6.50015-4","article-title":"Experimental Researches\non Specific Therapy: On Immunity with special Reference to the Relationship\nbetween Distribution and Action of Antigens. FIRST HARBEN LECTURE\n[Delivered in London, 5 June 1907]","volume-title":"The\nCollected Papers of Paul Ehrlich","author":"Erlich","year":"1960"},{"key":"2026091607070401400_cit2","first-page":"540","article-title":"Paul Ehrlich\nand his Magic Bullets - Revisited","volume":"143","author":"Witkop","year":"1990","journal-title":"Proc. Am.\nPhilos. Soc."},{"key":"2026091607070401400_cit3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/antib10040042","article-title":"Introduction\nto Antibody-Drug Conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies"},{"key":"2026091607070401400_cit4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events\nof antibody-drug conjugates in clinical trials: A systematic review\nand meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"2026091607070401400_cit5","doi-asserted-by":"publisher","first-page":"17588359241309461","DOI":"10.1177\/17588359241309461","article-title":"Innovative\npayloads for ADCs in cancer treatment: moving beyond the selective\ndelivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"7","key":"2026091607070401400_cit6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.trecan.2026.04.001","article-title":"Repurposing payloads:\nnext generation of antibody\u2013drug\nconjugates","volume":"12","author":"Shatzer","year":"2026","journal-title":"Trends Cancer"},{"key":"2026091607070401400_cit7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/00498254.2022.2141667","article-title":"ADME and DMPK considerations for\nthe discovery and development of antibody drug conjugates (ADCs)","volume":"52","author":"Beaumont","year":"2022","journal-title":"Xenobiotica"},{"key":"2026091607070401400_cit8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental\nand\ncomputational approaches to estimate solubility and permeability in\ndrug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv.\nDrug Delivery Rev."},{"key":"2026091607070401400_cit9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody\ndrug conjugates:\nA dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"2026091607070401400_cit10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates:\nA new era of\ntargeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discovery Today"},{"key":"2026091607070401400_cit11","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of\nPayload Hydrophobicity on the Stability of Antibody\u2013Drug Conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"2026091607070401400_cit12","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1021\/acs.jmedchem.1c02099","article-title":"Design and Development of Glucocorticoid\nReceptor Modulators as Immunology Antibody\u2013Drug Conjugate Payloads","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026091607070401400_cit13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/1735-5362.363591","article-title":"Sub-cellular\nsequestration of alkaline\ndrugs in lysosomes: new insights for pharmaceutical development of\nlysosomal fluid","volume":"18","author":"Yousef","year":"2023","journal-title":"Res. Pharm. Sci."},{"key":"2026091607070401400_cit14","doi-asserted-by":"publisher","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in\nantibody-drug conjugates: Navigating the fine\nline in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"2026091607070401400_cit15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2018.07.002","article-title":"Minireview:\nAddressing the retro-Michael\ninstability of maleimide bioconjugates","volume":"30","author":"Szijj","year":"2018","journal-title":"Drug\nDiscovery Today: Technol."},{"key":"2026091607070401400_cit16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1039\/9781788012898-00031","article-title":"Design factors\nimportant for Antibody-Drug Conjugates (ADCs)","volume-title":"Cytotoxic Payloads for Antibody\u2013Drug Conjugates","author":"Lambert","year":"2019"},{"key":"2026091607070401400_cit17","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-Drug\nConjugates: The New Frontier of Chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026091607070401400_cit18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","article-title":"Mechanisms of CYP450 Inhibition:\nUnderstanding Drug-Drug Interactions Due to Mechanism-Based Inhibition\nin Clinical Practice","volume":"12","author":"Deodhar","year":"2020","journal-title":"Pharmaceutics"},{"key":"2026091607070401400_cit19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","article-title":"Antibody Drug Conjugates:\nNonclinical Safety Considerations","volume":"17","author":"Hinrichs","year":"2015","journal-title":"AAPS J."},{"key":"2026091607070401400_cit20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1208\/s12248-025-01115-9","article-title":"Recent Advances\nin Bioanalytical Methods for Quantification\nand Pharmacokinetic Analyses of Antibody-Drug Conjugates","volume":"27","author":"Khan","year":"2025","journal-title":"AAPS J."},{"key":"2026091607070401400_cit21","doi-asserted-by":"publisher","first-page":"124608","DOI":"10.1016\/j.jchromb.2025.124608","article-title":"Versatile intact LC-MS method for\nevaluating the drug-antibody ratio and drug load distribution of antibody-drug\nconjugates in human plasma","volume":"1258","author":"Hashii","year":"2025","journal-title":"J. Chromatogr. B"},{"key":"2026091607070401400_cit22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ab.2011.01.004","article-title":"Characterization\nof intact antibody-drug conjugates from plasma\/serum\nin vivo by affinity capture capillary liquid chromatography-mass spectrometry","volume":"412","author":"Xu","year":"2011","journal-title":"Anal. Biochem."},{"key":"2026091607070401400_cit23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.dmpk.2018.02.003","article-title":"Importance\nof cynomolgus monkeys\nin development of monoclonal antibody drugs","volume":"34","author":"Iwasaki","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"key":"2026091607070401400_cit24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as\na target for drug\ndelivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Delivery Rev."},{"key":"2026091607070401400_cit25","doi-asserted-by":"publisher","first-page":"2484443","DOI":"10.1080\/19420862.2025.2484443","article-title":"Prediction\nof human pharmacokinetics of Fc-engineered therapeutic monoclonal\nantibodies using human FcRn transgenic mice","volume":"17","author":"Haraya","year":"2025","journal-title":"mAbs"},{"key":"2026091607070401400_cit26","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous\nantibody-drug conjugates with dual payloads: potential, methods and\nconsiderations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"},{"key":"2026091607070401400_cit27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","article-title":"Clinical implications\nof intratumor heterogeneity: challenges and opportunities","volume":"98","author":"Ramo\u0301n Y Cajal","year":"2020","journal-title":"J. Mol. Med."},{"key":"2026091607070401400_cit28","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3390\/cancers16122180","article-title":"Dose Optimization\nof Targeted Therapies for Oncologic Indications","volume":"16","author":"Zettler","year":"2024","journal-title":"Cancers"},{"key":"2026091607070401400_cit29","doi-asserted-by":"publisher","first-page":"114612","DOI":"10.1016\/j.jconrel.2026.114612","article-title":"The role of hydrophilic\nlinkers in\nnext-generation antibody-drug conjugates","volume":"391","author":"Fu","year":"2026","journal-title":"J.\nControlled Release"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00322","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1798\/67005196\/acs.bioconjchem.6c00322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/9\/1798\/67005196\/acs.bioconjchem.6c00322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:29:52Z","timestamp":1789558192000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/9\/1798\/5287599\/Beyond-Cytotoxic-Payloads-for-Antibody-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00322","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}